ERBB2 and breast cancer: In 2016, the phase 3 study PALOMA-2 showed that the addition of a CDK inhibitor to standard endocrine therapy significantly improved outcomes in the first-line treatment of ER-positive, HER2- negative advanced BC [61,62].